Default company panoramic image

Visionary Pharmaceuticals

Visionary Pharmaceuticals develops innovative, oral drugs for rheumatoid arthritis, inflammatory bowel disease, psoriasis, asthma and Cancer.

  • Stage Product In Development
  • Industry Biotechnology
  • Location San Diego, CA, USA
  • Currency USD
  • Founded June 2010
  • Employees 5
  • Website

Company Summary

Visionary Pharmaceuticals is a pharmaceutical company developing medicines to treat many clinically important autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, psoriasis, inflammatory bowel disease, asthma, COPD and others. These represent more than 300 million patients worldwide with a market exceeding $200 billion per year. Big Pharma are our customers. They will in-license our products for up-front cash.


  • Default avatar
    Gordon Robert Alton
    President and CEO

    Dr. Alton is the President and CEO of Visionary Pharmaceuticals. He implements the strategic direction of the company, oversees the technical and scientific programs and manages investor relations.

    Previously Dr. Alton founded Altonyx Consulting which provided drug discovery consulting services.

    He was formerly a Group Leader at Pfizer overseeing business development, academic collaborations and drug discovery.

  • Default avatar
    Ayse Batova
    VP of Biology

    Dr. Batova is currently faculty at the University of California, San Diego.Dr. Batova has investigated the molecular basis of T-cell acute lymphoblastic leukemia and neuroblastoma and has conducted pre-clinical evaluation of multiple target-based agents. She has authored numerous publications on these topics in peer-reviewed journals and has been invited to present her work at international meetings

  • Default avatar
    James Zapf
    Chief Science Officer

    Dr. Zapf is has several decades of experience in developing advanced computational algorithms to drive structure-based drug design. He has worked for several large pharmaceutical companies doing autoimmune drug discovery and holds patents on key enabling technologies.


  • Default avatar
    Michael Umansky, Partner at Sheppard-Mullin
    Default avatar
    Lous Tommasino, acting CFO